At the AMCP Annual Meeting this week, experts from Prime Therapeutics said virtual navigation and clinical pathways are ...
Scientists assumed that one specific immune cell subtype was required for mRNA vaccination to activate the immune system. But ...
Right to Try can allow certain patients with life-threatening conditions access to investigational treatments, but after ...
Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...
Multiple myeloma research led by researchers at the University of Calgary identified how tumor cells adapt after ...
Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...
Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...
PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results